> Curis announced that it is discontinuing a partnership with Genentech to co-develop a basal cell carcinoma candidate. They had already stopped a Phase I trial involved in the deal and had announced that they would not pursue a clinical evaluation of the therapy in that formulation. Report
> Invitrogen announced it is buying Sentigen in a $25.9 million deal. Sentigen said that its Tango Assay System and division arrested Assay Ready Cells will provide a boost to Invitrogen's work in assay development. Report
> The International Trade Commission has ruled that Roche did not violate any of Amgen's patents when it imported its anti-anemia drug CERA into the United States. Report
> Sunnyvale, CA-based Cepheid has won a $3.3 million grant to develop a test for the early detection of tuberculosis. Report
And Finally... The FDA is negotiating for higher user fees from the drug industry. Article